MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

February 14, 2018

New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease.

December 20, 2016

NEW YORK, DECEMBER 20, 2016—After 14 years of Chagas diagnoses, treatment and prevention efforts in Bolivia, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) ended its Chagas operations today by presenting Bolivia’s Ministry of Health with an operating manual for managing Chagas disease in rural areas.

November 10, 2016

Today is World Pneumonia Day. It's a somewhat abstract concept, associating a specific disease with a specific day, but the reality of pneumonia is very scary and dangerous, and possibly even deadly, for millions and millions of people around the globe.

Each year, pneumonia takes the lives of nearly one million children worldwide, often for want of a vaccine. There is in fact a vaccine to prevent it, something that's commonly administered to children in many western countries, but it’s too expensive for many countries to afford.

May 19, 2016

The O’Neill Report is the British Government’s response to tackling the emerging antibiotic resistance crisis. In order to overcome this global threat, all countries must play their part and take action to address the crisis, including funding research and development for new tools—new classes of antibiotics, but also diagnostics and vaccines—while ensuring sustainable and affordable access for those new tools. At the same time, steps need to be taken to conserve existing antibiotics for as long as possible.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

July 07, 2015

The crew of the Bourbon Argos, a search and rescue ship deployed by Doctors Without Borders/Médecins Sans Frontières (MSF), has been working save lives in the Mediterranean since May 7, 2015. In June alone, MSF workers on the ship rescued 1,057 migrants from dilapidated boats as they attempted to reach Europe.

April 14, 2015

SUCRE, BOLIVIA/NEW YORKDoctors Without Borders/Médecins Sans Frontières (MSF) is launching a new project to ensure that people can be diagnosed and treated for Chagas disease in the town of Monteagudo, in the Chuquisaca department of southern Bolivia. In partnership with local health care institutions, the international medical humanitarian organization will develop a comprehensive care model for primary and secondary care that will be integrated into the existing health care system.

Pages

February 14, 2018

New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease.

December 20, 2016

NEW YORK, DECEMBER 20, 2016—After 14 years of Chagas diagnoses, treatment and prevention efforts in Bolivia, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) ended its Chagas operations today by presenting Bolivia’s Ministry of Health with an operating manual for managing Chagas disease in rural areas.

November 10, 2016

Today is World Pneumonia Day. It's a somewhat abstract concept, associating a specific disease with a specific day, but the reality of pneumonia is very scary and dangerous, and possibly even deadly, for millions and millions of people around the globe.

Each year, pneumonia takes the lives of nearly one million children worldwide, often for want of a vaccine. There is in fact a vaccine to prevent it, something that's commonly administered to children in many western countries, but it’s too expensive for many countries to afford.

May 19, 2016

The O’Neill Report is the British Government’s response to tackling the emerging antibiotic resistance crisis. In order to overcome this global threat, all countries must play their part and take action to address the crisis, including funding research and development for new tools—new classes of antibiotics, but also diagnostics and vaccines—while ensuring sustainable and affordable access for those new tools. At the same time, steps need to be taken to conserve existing antibiotics for as long as possible.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

July 07, 2015

The crew of the Bourbon Argos, a search and rescue ship deployed by Doctors Without Borders/Médecins Sans Frontières (MSF), has been working save lives in the Mediterranean since May 7, 2015. In June alone, MSF workers on the ship rescued 1,057 migrants from dilapidated boats as they attempted to reach Europe.

April 14, 2015

SUCRE, BOLIVIA/NEW YORKDoctors Without Borders/Médecins Sans Frontières (MSF) is launching a new project to ensure that people can be diagnosed and treated for Chagas disease in the town of Monteagudo, in the Chuquisaca department of southern Bolivia. In partnership with local health care institutions, the international medical humanitarian organization will develop a comprehensive care model for primary and secondary care that will be integrated into the existing health care system.

Pages